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Other names: CMM3; MGC14458; PSK-J3 
Location: 12q14 
Local order: Telomeric to the OS9 (amplified in 
osteosarcoma 9), CENTG1 (centaurin, gamma 1) and 
TSPAN31 (tetraspanin 31, SAS) genes. Centromeric to 
the MARCH9 (membrane-associated ring finger 
(C3HC4) 9), CYP27B1 (cytochrome P450, family 27, 
subfamily B, polypeptide 1) and METTL1 
(methyltransferase like 1) genes. These seven genes are 
clustered within a genomic region of about 75 kb. 
DNA/RNA 
Description 
CDK4 is a relatively compact gene that spans 4.16 kb 
of genomic DNA on the long arm of chromosome 12, 
in the telomere-to-centromere orientation. The gene 
consists of eight exons of which the first exon is non-
coding. The start codon is located in the beginning of 
exon 2 and the stop codon in the beginning of exon 8. 
Transcription 
The CDK4 mRNA is 1.44 kb. In the Ensembl database, 
also a shorter, alternatively spliced transcript 
(Q96BE9_HUMAN) is listed, but there is no biological 
evidence for a function of this transcript or the 
polypeptide it may encode. 
Pseudogene 
The Ensembl database lists OTTHUMG00000011002 
(Vega gene RP11-414B7.1) on chromosome 1 as a 
processed pseudogene of CDK4. 
Protein 
Description 
The open reading frame encodes a 303 amino acid 
protein with an estimated molecular weight of 33.7 
kDa. CDK4 is member of the Ser-Thr protein kinase 
family and its catalytic domain extends from amino 
acid 6 to 295. 
Expression 
CDK4 is expressed in a variety of normal cells and 
tissues as well as in cancer cells. The protein is often 
 
 
Genomic organization of the CDK4 gene on chromosome 12. 
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overexpressed in human tumors (e.g. malignant 
melanoma, glioma, sarcoma and carcinomas of the 
breast, colon, lung, ovary and oral cavity). 
Localisation 
Nuclear or nuclear/cytoplasmic. 
Function 
CDK4 constitutes the catalytic subunit of a 
heterodimeric Ser/Thr protein kinase which is involved 
in controlling progression through the G1 phase of the 
cell cycle. The activating partner of CDK4 (the 
regulatory subunit) is one of the D-type cyclins: 
CCND1, CCND2 or CCND3. Once activated, the 
CDK4-cyclin D complex phosphorylates members of 
the retinoblastoma protein family (pRb, p107, p130). 
The activity of CDK4 is inhibited by the p16 (INK4A) 
protein, which interferes with the cyclin D-binding 
region. 
Homology 
CDK4 belongs to the mammalian Cdk family, which 
includes about 20 members. The cyclin-binding domain 
of CDK4 has the amino acid sequence PISTVRE. The 
overall identity of CDK4 to CDK1 is 42%. 
Mutations 
Germinal 
Germ-line mutations in the CDK4 gene have so far 
only been found in families with inherited malignant 
melanoma and multiple atypical nevi. There are six 
such families reported. The mutations affect the Arg 
encoded by codon 24, changing it either to Cys (two 
families) or to His (four families). 
Somatic 
Amplification of the chromosomal region that includes 
CDK4 is commonly seen in gliomas and several 
subgroups of sarcomas, and may also occur in other 
tumors such a malignant melanomas. Point mutations 









Familial cutaneous malignant 
melanoma 3 (CMM3) 
Sporadic malignant melanoma 
Note: Cases with wild-type BRAF and NRAS genes. 
Glioma 
Disease 
Anaplastic astrocytoma and glioblastoma multiforme. 
Sarcoma 
Disease 
In particular liposarcoma, alveolar rhabdomyosarcoma 
and osteosarcoma. 
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